Integrated analysis of RNA and DNA from the phase III trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer

PURPOSE: Response to a complex trastuzumab-based regimen is affected by multiple features of the tumor and its microenvironment. Developing a predictive algorithm is key to optimizing HER2-targeting therapy. METHODS: We analyzed 137 pre-treatment tumors with mRNA-seq and DNA exome sequencing from CA...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Cancer Res
मुख्य लेखकों: Tanioka, Maki, Fan, Cheng, Parker, Joel S, Hoadley, Katherine A, Hu, Zhiyuan, Li, Yan, Hyslop, Terry M, Pitcher, Brandelyn N, Soloway, Matthew G, Spears, Patricia A, Henry, Lynn N, Tolaney, Sara, Dang, Chau T, Krop, Ian E, Harris, Lyndsay N, Berry, Donald A, Mardis, Elaine R, Winer, Eric P, Hudis, Clifford A, Carey, Lisa A, Perou, Charles M
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2018
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214737/
https://ncbi.nlm.nih.gov/pubmed/30037817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3431
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन